Lutronic and Syneron-Candela Settle Lawsuit

Syneron Medical Ltd and Candela Corporation, and Lutronic Corp and Lutronic Aesthetics Inc, announce that they have entered into a mutually agreeable comprehensive settlement agreement ending the patent disputes between the companies.

Terms of the settlement agreement were not disclosed.

The mutually agreed-upon settlement, limited to Lutronic, protects Candela’s investment in Profound and its patented long pulse and temperature-controlled technology today and in the future. The settlement, through a sublicense from Syneron-Candela, allows Lutronic to market its product in the short pulse category, protecting Candela’s investment in the development of products in the long pulse category with a thermocouple.

For more information, read the full news release at www.prnewswire.com

Patent Infringement Suits Filed Against 18 Manufacturers and Distributors of Fractional RF Microneedle Systems

Syneron Medical Ltd and its subsidiary Candela Corporation (collectively, Syneron Candela) and Massachusetts General Hospital (MGH) filed patent infringement complaints against 18 manufacturers and distributors of fractional RF micro-needle dermatological treatment systems in both the U.S. International Trade Commission in Washington, D.C. and in federal district court.

The accused infringing products include Secret RF by ilooda Co., Ltd. and Cutera, Inc.; Fraxis Duo by ilooda Co., Ltd., Emvera Technologies, LLC and Rohrer Aesthetics, LLC; Fractora by Invasix Ltd., Invasix, Inc. and InMode MD Ltd.; Legend Pro by Lumenis Ltd and Pollogen Ltd; 3DEEP by EndyMed Medical Ltd. and EndyMed Medical Inc.; INTRAcel by Jeisys Medical, Inc. and Perigee Medical LLC; Infini by Lutronic, Corp. and Lutronic, Inc.; and Vivace by Sung Hwan E&B Co. Ltd, Aesthetics Biomedical, Inc. and Cartessa Aesthetics LLC.